Bio-Rad Laboratories has broadened its collection of recombinant monoclonal anti-idiotypic antibodies, adding specificities ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

GlaxoSmithKline plc (UK) (($GB:GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) is ...

Use of belimumab prior to vs after initiating immunosuppressants was linked to faster OGC tapering and fewer disease flares among patients with SLE.

Although obinutuzumab has not yet received FDA approval in lupus nephritis, findings from a recent survey conducted by ...

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks Premium ...

Early and late response and glucocorticoid-sparing effect of belimumab in patients with systemic lupus erythematosus with joint and skin manifestations: results from the belimumab in real life setting ...

Intravenous belimumab plus SOC vs placebo plus SOC was not linked to an increased risk for infection among patients with SLE.